Clinical-Scale Cultures of Cord Blood CD34 Cells to Amplify Committed Progenitors and Maintain Stem Cell Activity

Abstract

We developed a clinical-scale cord blood (CB) cell ex vivo procedure to enable an extensive expansion of committed progenitors—colony-forming cells (CFCs) without impairing very primitive hematopoietic stem cells (HSCs). CD34 ++ cells, selected from previously cryopreserved and thawed CB units, were cultured in two steps (diluted 1:4 after 6 days) in the presence of stem cell factor (SCF), fms-related tyrosine kinase 3 ligand (Flt-3L), megakaryocyte growth and development factor (MGDF) (100 ng/ml each), granulocyte-colony stimulating factor (G-CSF) (10 ng/ml) in HP01 serum-free medium. HSC activity was evaluated in a serial transplantation assay, by detection of human cells (CD45, CD33, CD19 and CFC of human origin) in bone marrow (BM) of primary and secondary recipient NOD/SCID mice 6–8 weeks after transplantation. A wide amplification of total cells (~350-fold), CD34 + cells (~100-fold), and CFC (~130-fold) without impairing the HSC activity was obtained. The activity of a particular HSC subpopulation (SRC CFC ) was even enhanced. Thus, an extensive ex vivo expansion of CFCs is feasible without impairing the activity of HSCs. This result was enabled by associating antioxidant power of medium with an appropriate cytokine cocktail (i.e., mimicking physiologic effects of a weak oxygenation in hematopoietic environment).